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Three simple and sensitive spectrophotometric methods are proposed for the determination of atenolol (ATN) in bulk drug and
tablets. The methods are based on the bromination of ATN by the bromine generated in situ by the action of the acid on the
bromate–bromide mixture followed by the determination of unreacted bromine by reacting with a ﬁxed amount of either meta-
cresol purple (MCP) and measuring the absorbance at 540nm (method A) and 445nm (method B) or erioglaucine (EGC) and
measuringtheabsorbanceat630nm(methodC).Beer’slawisvalidwithintheconcentrationrangesof1.0–20.0,2.0–40.0and1.0–
8.0μg/mL for method A, method B and method C, respectively. The calculated molar absorptivities were found to be 1.20×104,
4.51×103 and 3.46 × 104 L/mol · cm for method A, method B and method C, respectively. Sandell’s sensitivity values, correlation
coeﬃcients, limits of detection and quantiﬁcation are also reported. Recovery results were statistically compared with those of a
reference method by applying Student’s t-a n dF-test. The novelty of the present study is the measurement of two diﬀerent colors
using MCP, that is, red-pink color of MCP in acid medium at 540nm and yellowish-orange color of brominated MCP at 445nm.
1.Introduction
Atenolol (ATN), chemically known as 4-(2-hydroxy-3-[(1-
methylethyl) amino] propoxy) benzeneacetamide [1], is
a β1-selective (cardio selective) adrenoreceptor antagonist
drug used for antiangina treatment to relieve symptoms, im-
prove tolerance, and as an antiarrhythmic to help regulate
heartbeat and infections. It is also used in management of al-
cohol withdrawal, in anxiety states, migraine prophylaxis,
hyperthyroidism, and tremors [2]. The drug is oﬃcial in In-
dian Pharmacopoeia [3] which describes a UV-spectropho-
tometric method and also in British Pharmacopoeia [4]
which recommends high-performance liquid chromatogra-
phic (HPLC) method for its determination. Several methods
havebeenreportedforthedeterminationofATNinpharma-
ceuticaldosageformsandincludediﬀusereﬂectancespectro-
scopy [5], HPLC [6–26], high-performance thin-layer chro-
matographic (HPTLC) [27, 28], ultra performance liquid
chromatography (UPLC) [29], gas chromatography (GC)
[30, 31], nonsuppressed ion chromatography [32], ﬂo-
urometry [33, 34], diﬀerential scanning calorimetry (DSC)
and thermogravimetry (TG) [35], electrophoresis, [36–38]
voltammetry [39], ion-selective electrode- (ISE-) based pot-
entiometry [40], atomic absorption spectrometry (AAS)
[41], UV-spectrophotometry [42–50], visible spectrophoto-
metry [51–62], and titrimetry [60–62].
To the best of our knowledge, there are twelve reports on
the use of visible spectrophotometry for the determination
of ATN in pharmaceutical formulations. Agrawal et al.
[51] have reported a method based on the reaction of ATN
with hydroxylamine hydrochloride in NaOH medium fol-
lowed by the reaction of the resultant hydroxamic acid
derivative with FeCl3 to give a red-violet ferric hydroxama-
te complex. Assays based on charge transfer complexation
reaction of ATN with chloranilic acid have been reported
by Agarwal et al. [52]a n dY ue ta l .[ 53]. Korany et al. [54]
have developed a method based on the treatment of a CHCl3
extract of powdered tablets of atenolol with acetaldehyde, a2 Journal of Analytical Methods in Chemistry
halogenated benzoquinone reagent (chloranil, 2,5-dichloro-
benzoquinone, or 2,6-dibromobenzoquinone chlorimine),
and propan-2-ol. The slow reaction between ATN and
ammonium vanadate in sulphuric acid medium resulted
in two kinetic spectrophotometric methods (ﬁxed-concen-
tration method and ﬁxed-time method) [55]. Al-Ghannam
and Belal [56] used the reaction between ATN and 4-chloro-
7-nitrobenzo-2-oxa-1,3-diazole in borate buﬀer of pH 8 at
the boiling temperature for the kinetic spectrophotometric
assay of drug. The method developed by Hiremath et al. [57]
is based on the oxidation of atenolol by a known excess of
permanganate in alkaline media and determination of un-
reacted permanganate spectrophotometrically at 526nm.
Bashiret al. [58]h a v er e po rt edam et h odb a s edo nd et e rm i n -
ation of ATN in basic medium, followed by addition of sodi-
um nitroprusside to generate a coloured complex. Basavaiah
et al. [59] have reported a method based on the oxidation
of ATN by a measured excess of chloramine-T followed by
determination of the unreacted oxidant by a charge-transfer
complexation reaction involving metol and sulphanilic acid.
The assay method based on the oxidation of ATN by a
known excess of chloramine-T in acid medium followed by
determination of the unreacted oxidant by reacting with a
ﬁxedamountofeithermetanilyelloworindigocarminehave
been reported by Basavaiah et al. [60]. A similar method
[61] employed bromate-bromide mixture, methyl orange
as reagents in acid medium. An acid-base reaction employ-
ing phenol red has also been reported by the same authors
[62].However,manyoftheabovemethodssuﬀeredfromone
or other disadvantage like poor sensitivity, heating or extrac-
tion step, use of organic solvents, use of expensive chemical,
and/or complicated experimental setup as can be seen from
Table 1.
The aim of this study was to develop three new spec-
trophotometric methods for the assay of ATN based on bro-
mination of ATN by a green brominating agent (i.e., bromi-
ne-generated in situ). The methods use bromated-bromide
mixture, metacresol purple (MCP), and erioglaucine (EGC)
as reagents. The proposed methods are economical com-
pared to the previously reported chromatographic tech-
niques. Moreover, these methods are sensitive, simple, does
not involve heating or extraction step, and free from usage of
hazardous chemicals. Since inexpensive and easily available
chemicalsareused,thedevelopedmethods evidencelow cost
per analysis.
2. Experimental
2.1. Apparatus. All absorbance measurements were made on
a Systronics model 106 digital spectrophotometer (Systron-
ics, Ahmadabad, India) provided with 1cm matched quartz
cells.
2.2. Materials and Reagents. All chemicals and reagents used
were of analytical or pharmaceutical grade. Distilled water
was used to prepare the solutions.
(1) Bromate-Bromide Mixture (40, 80, and 18μg/mL). A
stock standard bromate-bromide mixture solution equiva-
lent to 500μg/mL KBrO3 was prepared by dissolving accu-
ratelyweighed50mgofKBrO 3 (S.D.FineChem.Ltd.,Mum-
bai, India) and 0.5g of KBr (Merck, Mumbai, India) in water
and diluted to the mark in a 100mL calibrated ﬂask. The
stock solution was diluted appropriately with water to get the
working concentrations of 40, 80, and 18μg/mL KBrO3 for
use in method A, method B, and method C, respectively.
(2) MetaCresol Purple Solution (80 and 200μg/mL). A
400μg/mL stock solution was ﬁrst prepared by dissolving
40mgofdye(LobaChemie,Mumbai,India)in2mLof0.1N
NaOH and diluted to volume with water in a 100mL cali-
brated ﬂask. The solution (400μg/mL) was diluted further
with water to get the working concentrations of 80μg/mL
and 200μg/mL MCP solutions.
(3) Erioglaucine Solution (300μg/mL). The solution was
prepared by dissolving 30mg of dye (Loba Chemie, Mumbai,
India) in water and diluting to the mark with water in a
100mL calibrated ﬂask.
(4) Hydrochloric Acid (5M and 1M). The solutions were
prepared by appropriate dilution of concentrated hydrochlo-
ric acid (S. D. Fine Chem. Ltd., Mumbai, India. Sp. gr. 1.18)
with water.
(5) Standard ATN Solution. Pharmaceutical grade atenolol
(ATN) certiﬁed to be 99.89% pure was gifted by Cipla India
Ltd., Mumbai, India, and was used as received without any
further puriﬁcation and analysis. A stock standard solution
equivalent to 200μg/mL ATN was prepared by dissolving
accurately weighed 50mg of pure drug with water in a
250mL calibrated ﬂask. This stock solution was diluted ap-
propriately with water to get the working concentrations of
40μg/mL for use in methods A and C, and 80μg/mL for use
in method B.
2.3. Assay Procedure
2.3.1. Method A (Measuring MCP in Acid Medium). Dif-
ferent aliquots (0.25–5.0mL) of standard ATN solution
(40μg/mL) were accurately transferred into a series of 10mL
calibratedﬂasksusingmicroburetteandthetotalvolumewas
adjusted to 5.0mL by adding requisite volume of water. To
each ﬂask, 2mL of 5M HCl was added followed by 1mL of
bromate-bromide mixture (40μg/mL in KBrO3). The con-
tent was mixed well and the ﬂasks were allowed to stand
for 15min with occasional shaking. Then, 1mL of 80μg/mL
MCP was added to each ﬂask, diluted to the mark with
water, mixed well, and the absorbance of each solution was
measured at 540nm against a reagent blank after 5min.
2.3.2. Method B (Measuring Brominated Product of MCP).
Varying aliquots (0.25–5.0mL) of a standard solution
(80μg/mL ATN) were accurately measured into a series of
10mL calibrated ﬂasks and the total volume was brought toJournal of Analytical Methods in Chemistry 3
Table 1: Comparison of the proposed and the existing visible spectrophotometric methods.
Sl.
No. Reagent/s used Reagent used λmax
(nm)
Linear range,
μg/mL and
ε,L / m o l·cm
LOD,
μg/mL
Reaction
time, min Remarks Reference
(1)
Hydroxylamine
hydrochloride-
iron
(III)
Ferric hydroxamate
complex measured 510 50–800
(ε = 5.3 ×102) NR 20–30
Less sensitive,
heating
required
[51]
(2) Chloranilic acid Charge transfer
complex measured 534 25–250 NR —
Less sensitive,
use of organic
solvents
[52]
(3) Chloranilic acid Charge transfer
complex measured 530 10–280 NA NA -do- [53]
(4) Acetaldehyde-
Chloranil 690 NA NA NA Use of organic
solvents [54]
(5) NH4VO3
Reaction rate
measured 750 NA NA NA Heating
required [55]
(6)
4-chloro-7-
nitrobenzo-2-oxa-
1,3-diazole
Coupling product
measured as a
function of time
460 5–50 1.3 30 Heating
required [56]
(7)
Potassium
permanganate- in
alkaline medium
Unreacted KMnO4
measured 526 4 hrs Time-
consuming,
involve judicial
control of many
experimental
variables
[57]
Rate-constant
method 6.66–10.65
Fixed-concentration
method 6.66–5.33
Fixed-time method 6.66–7.99
(8) Sodium
nitroprusside
Complex of
ammonia and
nitroprusside
measured
495 0.5–30
(ε = 3.01 ×105) 0.01 5 Heating
required [58]
(9)
Chloramine-T-
metol-sulphanilic
acid
Unreacted
chloramine-T
measured
520 2.5–25
(ε = 3.24 ×103) 2.34 20 Less sensitive [59]
(10)
Chloramine-T:
(a) Metanil yellow
Unreacted
chloramine-T
measured
530 1–12
(ε = 1.19 ×104) 0.32 10 [60]
(b) Indigo
carmine 610 2.5–20
(ε = 6.65 ×103) 0.04 10
(11)
Bromate-bromide
mixture- methyl
orange
Unreacted bromine
measured 520 0.5–4.0
(ε = 4.13 ×104) 0.07 15 [61]
(12) Phenol red
The change in the
color of phenol red
measured
430 3.0–30
(ε = 3.47 ×103) 4.61 — Less sensitive [62]
(13)
Bromate-bromide
mixture:
Simple,
sensitive and no
heating step. No
use of organic
solvent. Use of
an eco-friendly
brominating
reagent.
This
work (a) MCP Unreacted MCP in
acid measured 540 1.0–20.0
(ε = 1.20 ×104) 0.12 15
(b) MCP Bromo-derivative of
MCP measured 445 2.0–40.0
(ε = 4.51 ×103) 0.56 10
(c) EGC Unreacted EGC in
acid measured 630 1.0–8.0
(ε = 3.46 ×104) 0.05 10
MCP: metacresol purple, EGC: erioglaucine, NR: not reported, NA: not available.4 Journal of Analytical Methods in Chemistry
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Figure 1: Method A: 1mL 80μg / m LM C P ;2m L5MH C l .M e t h o dB :B r o m i n a t e dp r o d u c to fM C P( 1m L4 0μg/mL bromated-bromide
mixture; 2mL 5M HCl; 1mL 80 μg/mL MCP). Method C: Sample: 1mL 40μg/mL ATN; 5mL 1M HCl; 1mL 18μg/mL bromated-bromide
mixture; 1mL 300μg/mL EG. Blank: 5mL 1M HCl; 1mL 18μg/mL bromated-bromide mixture; 1mL 300μg/mL EG.
5mL by adding water. To each ﬂask were added 2mL of 5M
HCland1mLofKBrO3-KBrsolution(80μg/mL,inKBrO3).
The content of each ﬂask was mixed well and kept aside for
10min with occasional swirling. At last, 1mL of 200μg/mL
MCP solution was added to each ﬂask and diluted up to
the mark with water. The absorbance of each solution was
measured after 5min at 445nm against water.
2.3.3. Method C (Using EGC). Aliquots (0.25–2.0mL) of a
standard ATN (40μg/mL) solution were accurately trans-
ferred into a series of 10mL calibrated ﬂasks and the total
volume was adjusted to 2.0mL with water. To each ﬂask,
5mL of 1M HCl was added followed by 1.0mL of bromate-
bromide mixture (18μg/mL, in KBrO3). The content was
mixedandtheﬂaskswereletstandfor10minwithoccasional
shaking followed by addition of 1mL of 300μg/mL EGC
to each ﬂask. The solutions were diluted to the mark with
water, mixed well, and the absorbance of each solution was
measured at 630nm after 5min against a reagent blank.
2.3.4. Analysis of Commercial Tablets. Twenty tablets each
containing25,50,or100mgofATNwereweighedaccurately
and pulverized. An amount of powdered tablet equivalent to
20mg of ATN was transferred into a 100mL calibrated ﬂask
and 60mL of water was added. The content was shaken thor-
oughly for about 15–20min, diluted to the mark with water,
mixed well, and ﬁltered using a Whatman No. 42 ﬁlter paper.
The ﬁrst 10mL portion of the ﬁltrate was discarded and a
suitable aliquot of the ﬁltrate (200μg/mL ATN) was diluted
to get the working concentrations of 40μg/mL ATN for the
assay by methods A and C, and 80μg/mL ATN for method B.
2.3.5. Analysis of Placebo Blank. A placebo blank of the
composition: talc (45mg), starch (35mg), acacia (25mg),
methyl cellulose (40mg), sodium citrate (25mg), magne-
sium stearate (35mg), and sodium alginate (30mg) was
made and its solution was prepared in 25mL calibration
ﬂask as described under Section 2.3.4, and then subjected to
analysis using the procedures described above.
2.3.6. Analysis of Synthetic Mixture. To the placebo blank
of the composition described above, 20mg of ATN was
added and homogenized, transferred to a 100mL calibrated
ﬂask, and the solution was prepared as described under
Section 2.3.4, and then subjected to analysis by the proce-
dures described above. The analysis was used to study the
interferences of excipients such as talc, starch, acacia, methyl
cellulose, sodium citrate, magnesium stearate, and sodium
alginate.
3. Results and Discussion
3.1. Absorption Spectra. The proposed methods are based
on the determination of residual bromine generated in situ
after the reaction between the drug and bromine is judged
to be complete. The red-pink color of unreacted MCP in
acid medium was absorbed maximally at 540nm (method
A). The residual bromine was then used to brominate MCP
yielding yellow-colored bromo-derivative product with λmax
at 445nm (method B). Similar to method A, the green
color of unreacted EGC in acid medium peaked at 630nm
(method C). The absorption spectra of all methods are
presented in Figure 1.Journal of Analytical Methods in Chemistry 5
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Figure 2: Tentative reaction scheme for the proposed methods.
3.2. Chemistry. Atenolol is reported to undergo bromination
by bromine generated in situ by the action of the acid on the
bromate-bromide mixture [61]. The solution of bromate-
bromide mixture in acid medium behaves as an equivalent
solution of bromine and has been used for the assay of
several pharmaceutical compounds [63–66]. The present
investigation deals with three spectrophotometric methods
for the assay of ATN using bromine generated in situ as
eco-friendly brominating agent and avoiding the use of
highly toxic and hazardous liquid bromine. The proposed
methods are indirect and based on the bromination of ATN
by the bromine followed by the determination of unreacted
bromine by reacting with a ﬁxed amount of either MCP
or EGC and measuring the absorbance at the respective
wavelengths. The reaction between ATN and bromine gen-
erated in situ uses electrophilic substitution reaction at one
orthoposition to the alkoxy group on the benzene ring.
The unreacted bromine was determined by its reaction with
either MCP or EGC. The reaction of bromine with MCP
involved two simultaneous processes, that is, decrease in the
pink color of MCP in acid medium at 540nm (method
A) and increase in the yellowish-orange color at 445nm
(method B) due to the bromination of the dye. Similar to
methodA,unreactedbrominewouldreactwithEGCandthe
decrease in the absorbance of the green color of EGC in acid
medium was measured at 630nm (method C). The tentative
reaction scheme is given and illustrated in Figure 2.
3.3. Basis of the Methods. ATN, when added in increasing
concentrations to a ﬁxed concentration of in situ bromine,
consumed the latter and there occurred a concomitant fall
in bromine concentration. When a ﬁxed concentration of
MCP was added to decreasing concentrations of bromine,
a concomitant increase in the absorbance of MCP resulted
at 540nm and at the same time decrease in the absorbance
resulted at 445nm. Similarly, when a ﬁxed concentration of
EGC was added to decreasing concentrations of bromine,
a corresponding increase in the absorbance of EGC was
observed at 630nm. These were observed as a proportional
increase in the absorbance at 540nm (method A) or 630nm
(method C) and decrease at 445nm (method B) with
increasing the concentration of ATN.
3.4. Optimization of Reaction Variables
3.4.1. Eﬀect of Reagent Concentration. Preliminary experi-
mentswereperformedtoﬁxtheupperlimitsoftheMCPand
EGC that could produce a reasonably high absorbance, and
these were found to be 80, 200μg/mL for MCP in methods
A and B, and 300μg/mL for EGC in method C. Bromate
concentrations of 4.0 and 1.8μg/mL in the presence of excess
bromide were found optimum to bleach the dye color in
method A and method C, respectively, whereas 8.0μg/mL
KBrO3 produced a reasonable maximum absorbance at6 Journal of Analytical Methods in Chemistry
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Figure 3: Eﬀect of acid on the color development of the measured species for the proposed methods.
Table 2: Regression and analytical parameters.
Parameter Method A Method B Method C
λmax, nm 540 445 630
Beer’s law limits (μg/mL) 1–20 2–40 1–8
Molar absorptivity (L/mol·cm) 1.20 ×104 4.51 ×103 3.46 ×104
Sandell sensitivity∗ (μg/cm2) 0.0223 0.0591 0.0077
Limit of detection (μg/mL) 0.12 0.56 0.05
Limit of quantiﬁcation (μg/mL) 0.36 1.69 0.14
Regression equation, Y∗∗
Intercept 0.0038 0.7755 0.0217
Slope 0.0443 −0.0154 0.1229
Correlation coeﬃcient (r) 0.9996 −0.9973 0.9992
Standard deviation of intercept (Sa) 0.00664 0.08471 0.01436
Standard deviation of slope (Sb) 0.00059 0.00378 0.00292
∗Limit of determination as the weight in μg per ml of solution, which corresponds to an absorbance of A = 0.001 measured in a cuvette of cross-sectional
area 1cm2 and l = 1cm. ∗∗Y = a+ bX,w h e r eY is the absorbance, a is the intercept, b is the slope, and X is the concentration in μg/mL.
445nm in method B. Hence, diﬀerent concentrations of
ATN were reacted with 1.0mL each of 40, 80, and 18μg/mL
bromate in methods A, B, and C, respectively.
3.4.2. Eﬀect of Reaction Medium. Hydrochloric acid was
found to be an ideal medium for the two steps involved in all
thethreemethods(Figure 3).InmethodA,theeﬀectof(1.0–
3.0mL of 5M HCl) was studied and the results showed that
2.0mL of 5M HCl was optimum for the bromination reac-
tion of the drug as well as the dye. Taking in to account the
maximum absorbance of the measured species and the min-
imum absorbance of the blank, 2.0mL of 5M HCl was ﬁxed.
In method B, 2.0mL of 5M HCl was found optimum and
anyexcessoftheacidupto3.0mLwouldnotaﬀecttheabsor-
bance of the measured species. In method C, 5.0mL of 1M
HCl was found optimum to achieve maximum absorbance
for the sample and minimum absorbance for the blank.
3.4.3. Reaction Time and Color Stability. The reaction time
between ATN and the bromine generated in situ was found
to be 15min in method A and 10min in both method B and
method C. After completion the reaction between the drug
and the bromine, the residual bromine would brominate
the dyes and this bromination process was found to be
complete in 5min for all three methods. The absorbance of
the measured species was constant up to 24 hours.
3.5. Validation of the Proposed Methods
3.5.1. Linearity. A linear relation is found between absor-
bance and concentration of ATN within Beer’s law range
given in Table 2. The calibration graphs are described by the
equation:
Y = a + bX ,( 1 )Journal of Analytical Methods in Chemistry 7
Table 3: Evaluation of intraday and interday precision and accuracy.
Method ATN taken(μg/mL) Intraday (n = 7) Interday (n = 5)
ATN found
a (μg/mL ) %RSD
b %RE
c ATN found
a (μg/mL ) %RSD
b %RE
c
Method A
4.00 4.14 1.49 1.71 4.09 1.86 2.25
8.00 8.12 0.75 1.56 8.16 1.34 2.00
12.00 4.0 0.67 1.04 12.31 1.28 2.58
Method B
8.00 8.22 1.74 2.69 8.19 2.14 2.38
16.00 16.25 1.06 1.58 16.44 2.08 2.75
24.00 24.63 0.56 2.62 24.85 1.72 3.54
Method C
2.00 1.99 1.64 0.46 2.05 2.14 2.50
4.00 4.09 2.09 2.44 4.14 2.56 3.50
6.00 6.07 1.47 1.09 6.16 2.63 2.67
aMean value of ﬁve determinations; brelative standard deviation (%); crelative error (%).
Table 4: Robustness and ruggedness.
Method ATN taken,
μg/mL
Method robustness Method ruggedness
Parameters altered
Volume of acid, ml
a
RSD, % (n = 3)
Reaction time
b
RSD, % (n = 3)
Interanalysts’
RSD, % (n = 3)
Inter instruments’
RSD, % (n = 3)
A
4.00 1.26 1.46 1.34 2.64
8.00 0.72 1.72 0.85 3.18
12.00 0.64 1.28 1.03 3.03
B
8.00 0.85 1.39 1.42 2.86
16.00 0.52 0.92 1.17 2.47
24.00 1.18 1.15 1.33 3.26
C
2.00 1.26 1.26 1.06 3.42
4.00 0.96 1.39 0.88 2.78
6.00 1.08 0.76 1.24 2.37
aIn methods A and B, the volume of 5M HCl was 1.8, 2.0, and 2.2mL whereas in method C, the volume of 1 MHCl was 4.8, 5.0, and 5.2mL b The reaction
time in methods A was 14, 15, and 16min whereas in methods B and C, the same was 9, 10, and 11min.
Table 5: Results of analysis of tablets by the reference and proposed methods.
Tablet Brand name Label claim mg/tablet
Found (percent of label claim ± SD)a
Reference method Proposed methods
Method A Method B Method C
Atenex-25b 25 100.3 ±0.58
100.9 ±1.06 99.65 ±0.96 101.0 ± 1.12
t = 1.11 t = 1.2 t = 1.28
F = 3.34 F = 2.74 F = 3.33
Atekind-50c 50 99.67 ±0.67
101.0 ±1.09 100.6 ±1.36 99.81 ± 1.42
t = 2.32 t = 1.42 t = 0.20
F = 1.48 F = 4.12 F = 4.49
Aten-100d 100 100.6 ±0.82
100.6 ±1.11 101.1 ±1.37 99.72 ± 1.69
t = 0.03 t = 0.69 t = 1.05
F = 1.83 F = 2.79 F = 4.25
aMean value of ﬁve determinations. b,dMarketed by Zydas Healthcare, East Sikkim, India, c Marketed by Mankind Pharma Ltd., New Delhi, India, Tabulated
t-value at the 95% conﬁdence level is 2.78. Tabulated F-value at the 95% conﬁdence level is 6.39.8 Journal of Analytical Methods in Chemistry
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(where Y = absorbance, a = intercept, b = slope and X =
concentration in μg/mL) obtained by the method of least
squares. The apparent molar absorptivity (ε), Sandell’s sensi-
tivity, limits of detection (LOD), and quantiﬁcation (LOQ)
are also given in the Table 2. Limits of detection (LOD) and
quantiﬁcation (LOQ) were calculated from the following
equations [67]:
LOD =
3.3 ×σ
S
,
LOQ =
10 ×σ
S
,
(2)
where σ is the standard deviation of “n”r e a g e n tb l a n kd e t e r -
minations and S is the slope of the calibration curve.
3.5.2. Accuracy and Precision. In order to study the precision
and accuracy of the proposed methods, three concentrations
of pure ATN within the linearity range were analyzed, each
determination being repeated seven times (intraday preci-
sion) in the same day and one time each for ﬁve days (inter-
day precision). The percentage relative standard deviation
(%RSD) was ≤2.09% (intraday) and ≤2.63% (interday). In
addition,theaccuracyoftheproposedmethodwasmeasured
bycalculatingthepercentagerelativeerror(%RE),whichwas
varied between 0.46% and 3.54%. The results of this study
indicate the high accuracy and precision of the proposed
methods (Table 3).
3.5.3. Robustness and Ruggedness. To evaluate the robustness
of the methods, two important experimental variables,
namely, the amount of acid and reaction time, were slightly
varied, and the capacity of the methods was found to remain
unaﬀected by small deliberate variations. The results of this
study are presented in Table 4 and indicate that the proposed
methods are robust. Method ruggedness is expressed as
%RSD of the same procedure applied by three analysts and
usingthreediﬀerentspectrophotometersbythesameanalyst.
The interanalysts’ and interinstruments’ RSD values were
≤3.42%indicatingruggednessoftheproposedmethods.The
results of this study are presented in Table 4.
3.5.4. Selectivity. In the present methods, a study of some
potential interference was performed by selecting the excip-
ients often used in pharmaceutical formulations or as pos-
sible coactive substances. Selectivity was evaluated by both
placebo blank and synthetic mixture analyses. The placebo
blank, consisting the composition as mentioned under
Section 2.3.5 was prepared and analyzed as described under
the recommended procedures. The resulting absorbance
readings for the methods were the same as the reagent blank,
inferring no interference from the placebo. The selectivity of
the methods was further conﬁrmed by carrying out recovery
study from synthetic mixture. The percent recoveries of ATN
were 102.1±1.35, 101.9±1.18, and 101.4±1.63 for method
A, method B, and method C, respectively. This conﬁrms the
selectivity of the proposed methods in the presence of the
commonly employed tablet excipients.
3.5.5. Application to Analysis of Pharmaceutical Samples. The
proposed methods were successfully applied to the deter-
mination of ATN in three diﬀerent brands of tablets, namely,
Atenex-25, Atekind-50, and Aten-100. The results presented
in Table 5 showed that there was a close agreement between
the results obtained by the proposed methods and the label
claim. The results were also compared with those of the
reference method [3] statistically by a Student’s t-t e s tf o r
accuracy and variance ratio F-test for precision at 95% conf-
idence level. The reference method consisted of the measure-
ment of the absorbance of the methanolic tablet solution at
275nm. The calculated t-a n dF-values indicate that there is
no signiﬁcant diﬀerence between the proposed methods and
the reference method with respect to accuracy and precision.
3.5.6. Recovery Studies. To study the reliability of the pro-
posed method, a standard addition technique was followed.
Aﬁ x e da m o u n to fd r u gf r o mp r e a n a l y z e dt a b l e tp o w d e rw a s
taken and pure drug at three diﬀerent concentrations (50,
100, and 150% of that in tablet powder) was added. The
totalconcentrationwasfoundbytheproposedmethods.The
determination with each concentration was repeated three
times and the percent recovery of the added standard was
calculated. Results of this study presented in Table 6 reveal
that the accuracy of methods was unaﬀected by the various
excipients present in the formulations.
4. Conclusions
Threesensitivespectrophotometricmethodsforthedetermi-
nation of ATN have been developed and validated based on
the current ICH guidelines [67]. The present methods dem-
onstrate that bromate-bromide mixture and metacresol pur-
ple or erioglaucine can be used for the quantitative determi-
nation of ATN in bulk drug as well as in tablets. The propos-
ed methods have the advantages of utilization of bromine
generated in situ as a green brominating reagent, free from
critical experimental conditions, and complicated proce-
dures such as heating or extraction step. The reagents used
in the proposed methods are cheap, readily available, and the
procedures do not involve any tedious sample preparation.
These advantages encourage the application of the proposed
methods in routine quality control analysis of ATN in phar-
maceutical formulations.
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